Lung cancer immunotherapy trial pulled before it began
NCT ID NCT06572722
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study aimed to compare three different immunotherapy approaches (atezolizumab, nivolumab, and pembrolizumab) given before and after surgery for people with early-stage non-small-cell lung cancer. The goal was to see which approach best prevented the cancer from coming back. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.